Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Min Yuen Teo

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Nature Reviews. Clinical Oncology|November 9, 2017
Drug development for noncastrate prostate cancer in a changed therapeutic landscapeMin Yuen Teo, Matthew J O'Shaughnessy, Sean M McBride, et al.
Frontiers in Oncology|July 30, 2024
Toxicity of immune checkpoint inhibitors and tyrosine kinase inhibitor combinations in solid tumours: a systematic review and meta-analysisDavid O'Reilly, Caroline L O'Leary, Aislinn Reilly, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|November 15, 2023
Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRISungmin Woo, Anton S Becker, Jeeban P Das, et al.
Clinical Genitourinary Cancer|December 14, 2021
Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 PatientsSungmin Woo, Chong Hyun Suh, Andreas G Wibmer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 3, 2021
Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint InhibitorsJose Mauricio Mota, Min Yuen Teo, Karissa Whiting, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Hypofractionated Radiation Therapy (Hypo-RT) for the Treatment of Localized Bladder CancerAssaf Moore, Stephanie M Lobaugh, Zhigang Zhang, et al.
Cancer Research|January 14, 2017
ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder CancerTomasz B Owczarek, Takashi Kobayashi, Ricardo Ramirez, et al.
BMJ Oncology|August 1, 2024
Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysisElias B A Chandran, Giovanni Maria Iannantuono, Saad O Atiq, et al.
Cancer Medicine|December 31, 2020
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tractMichal Sarfaty, Karissa Whiting, Min Yuen Teo, et al.
Journal for Immunotherapy of Cancer|June 24, 2020
DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapyYasser Ged, Joshua L Chaim, Renzo G DiNatale, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Nature Reviews. Clinical Oncology|November 9, 2017
Drug development for noncastrate prostate cancer in a changed therapeutic landscapeMin Yuen Teo, Matthew J O'Shaughnessy, Sean M McBride, et al.
Frontiers in Oncology|July 30, 2024
Toxicity of immune checkpoint inhibitors and tyrosine kinase inhibitor combinations in solid tumours: a systematic review and meta-analysisDavid O'Reilly, Caroline L O'Leary, Aislinn Reilly, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|November 15, 2023
Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRISungmin Woo, Anton S Becker, Jeeban P Das, et al.
Clinical Genitourinary Cancer|December 14, 2021
Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 PatientsSungmin Woo, Chong Hyun Suh, Andreas G Wibmer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 3, 2021
Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint InhibitorsJose Mauricio Mota, Min Yuen Teo, Karissa Whiting, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Hypofractionated Radiation Therapy (Hypo-RT) for the Treatment of Localized Bladder CancerAssaf Moore, Stephanie M Lobaugh, Zhigang Zhang, et al.
Cancer Research|January 14, 2017
ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder CancerTomasz B Owczarek, Takashi Kobayashi, Ricardo Ramirez, et al.
BMJ Oncology|August 1, 2024
Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysisElias B A Chandran, Giovanni Maria Iannantuono, Saad O Atiq, et al.
Cancer Medicine|December 31, 2020
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tractMichal Sarfaty, Karissa Whiting, Min Yuen Teo, et al.
Journal for Immunotherapy of Cancer|June 24, 2020
DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapyYasser Ged, Joshua L Chaim, Renzo G DiNatale, et al.
Pageof 5